BackSinovac Biotech, Overview

Sinovac Biotech, Receivables

Latest receivables for SVA: $310M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$313.09M

Peer trimmed avg / median

Loading

Sinovac Biotech, Receivables History

Loading

Sinovac Biotech, vs. peers: Receivables Comparison

Loading

Sinovac Biotech, Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sinovac Biotech, (SVA) FAQ

Sinovac Biotech, (SVA) currently reports a receivables of $310M as of December 2025. Use the charts on this page to explore Sinovac Biotech,'s receivables history and peer comparisons.

Sinovac Biotech, reported $310M in receivables as of December 2025. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $310M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sinovac Biotech,, and consider following SVA for alerts when major investors trade the stock.

Sinovac Biotech, is classified in the Healthcare sector. On receivables, it currently shows $310M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SVA with unrelated industries.